Trial Profile
Evaluation of Effect and Tolerance of the Association of Baricitinib (4 mg) and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo: a Randomized, Double-blind, Prospective, Non-comparative Phase II Study.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Jun 2023
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary)
- Indications Vitiligo
- Focus Proof of concept; Therapeutic Use
- Acronyms BARVIT
- 12 Jun 2023 Status changed from active, no longer recruiting to completed.
- 12 May 2022 Status changed from recruiting to active, no longer recruiting.
- 21 Jan 2022 Status changed from not yet recruiting to recruiting.